Cheryl R. Blanchard, Ph.D., became the President and CEO of Anika Therapeutics in April 2020, stepping up from her role as interim CEO just two months earlier. Her journey at Anika began in 2018 when she joined the Board of...

Cheryl R. Blanchard, Ph.D., became the President and CEO of Anika Therapeutics in April 2020, stepping up from her role as interim CEO just two months earlier. Her journey at Anika began in 2018 when she joined the Board of Directors. Before Anika, Dr. Blanchard led Microchips Biotech, a company focused on regenerative medicine, until it was sold. She also held high-level positions at Zimmer Biologics, where she managed a team that created a successful regenerative medicine business worth over $100 million. Dr. Blanchard’s educational background is strong: she earned her Ph.D. and M.S. in Materials Science from the University of Texas at Austin and her B.S. in Ceramic Engineering from Alfred University. She has served on several boards, including Vigil Neuroscience and Daré Bioscience, reflecting her expertise in medical devices and pharmaceuticals. Her leadership philosophy aligns with Anika’s mission of improving patient outcomes, making her a key player in their innovative development. Notably, her total compensation in 2020 was around $984,000, illustrating her role's significance in guiding the company towards growth and success.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Anika Therapeutics CEOs

A

Cheryl R. Blanchard

Ex-CEO of Anika Therapeutics

Sector of Economy

Healthcare

CEO of Anika Therapeutics for

0 years 4 months (Feb 2020 - Jun 2020)

Previous Experience

Unknown

Rivals

Competitors/colleagues of Cheryl R. Blanchard

Holdings

See how much did Cheryl R. Blanchard make over time.

Dr. Cheryl Blanchard's holdings primarily reside in Anika Therapeutics. Following her appointment as CEO in April 2020, her wealth was significantly tied to her position in the company, particularly in restricted stock units (RSUs) intended to reward her for long-term...

Dr. Cheryl Blanchard's holdings primarily reside in Anika Therapeutics. Following her appointment as CEO in April 2020, her wealth was significantly tied to her position in the company, particularly in restricted stock units (RSUs) intended to reward her for long-term performance. By 2020, Dr. Blanchard had vested stock worth about $303,640 from her previous roles. Notably, the equity she acquired consists of 73,726 shares in time-based restricted stock units that were granted based on her performance and loyalty to the company. This strategy aligns her financial success with the company’s growth, showing that as Anika's value increases, so does her overall wealth. The shares she accrued provide stability and a vested interest in Anika’s long-term future and innovation within the healthcare sector.

Mar 18, 2025

A

shares

ANIK @ $15.86

D

shares

DARE @ $2.97

Insider Trading

See recent insider trades of Cheryl R. Blanchard.

ANIK

$207.25K

ANIK at $25.59/share

Mar 11, 2022

Purchase

ANIK

3,842 shares

ANIK

Feb 26, 2019

Received

ANIK

3,624 shares

ANIK

Aug 31, 2018

Received

Compensation History

See how much did Cheryl R. Blanchard make over time.

In 2020, Dr. Cheryl Blanchard’s total compensation was about $984,000. This package included a base salary of $625,000 and a cash bonus of around $331,000, which was partially tied to her performance and retention as a key leader. There were also significant contributions to her retirement plan and other benefits, raising her total earnings. Anika’s approach to compensation emphasizes aligning CEO pay with company performance and values, aiming to incentivize long-term growth and success. This balance is important for motivating leadership while ensuring they remain accountable to shareholders and the broader mission of the company. The compensation structure reflects both short-term and long-term goals, putting a focus on impactful results.

Year

2020

Total Compensation

$1.29M

Salary

$625.00K

Board Justification

The compensation philosophy is designed to drive long-term high performance and increase stockholder value through competitive compensation packages that align with company performance and individual contributions.

Bonus

$331.01K

Board Justification

This amount reflects the discretionary prorated cash bonus earned for the indicated year of $331,010 and a cash retention bonus of $127,500 provided under the terms of the interim Chief Executive Officer letter agreement entered into between the company and Dr. Blanchard.

Other

$27.96K

Board Justification

This amount includes matching contributions to the 401(k) Plan and group term life insurance premiums.

Restricted Stock

$303.64K(8.07K RSU)

Board Justification

This amount includes 3,842 restricted stock units granted to Dr. Blanchard as an independent director on February 26, 2019 that vested in 2020.

Performance Metrics

The performance metrics include revenue growth, adjusted EBITDA, and individual performance contributions.

Other Anika Therapeutics CEOs

Here are other CEOs of Anika Therapeutics

Joseph Darling

Ex-CEO of Anika Therapeutics

January 2019 - January 2020

Michael Levitz

Ex-CEO of Anika Therapeutics

July 2020 - May 2024